Nisa Investment Advisors LLC Has $35,000 Stock Holdings in Phreesia, Inc. (NYSE:PHR)

Nisa Investment Advisors LLC trimmed its position in Phreesia, Inc. (NYSE:PHR) by 25.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,494 shares of the company’s stock after selling 515 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Phreesia were worth $35,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. FMR LLC lifted its position in shares of Phreesia by 8.6% in the third quarter. FMR LLC now owns 7,856,551 shares of the company’s stock valued at $146,760,000 after buying an additional 624,456 shares during the last quarter. Rock Springs Capital Management LP boosted its position in Phreesia by 36.1% during the third quarter. Rock Springs Capital Management LP now owns 1,776,391 shares of the company’s stock worth $33,183,000 after purchasing an additional 471,391 shares during the period. TimesSquare Capital Management LLC increased its holdings in shares of Phreesia by 7.8% in the third quarter. TimesSquare Capital Management LLC now owns 774,079 shares of the company’s stock valued at $14,460,000 after purchasing an additional 55,793 shares during the last quarter. Blair William & Co. IL increased its holdings in shares of Phreesia by 72.6% in the third quarter. Blair William & Co. IL now owns 478,414 shares of the company’s stock valued at $8,937,000 after purchasing an additional 201,291 shares during the last quarter. Finally, CI Investments Inc. raised its position in shares of Phreesia by 6.6% in the third quarter. CI Investments Inc. now owns 477,265 shares of the company’s stock valued at $8,915,000 after purchasing an additional 29,500 shares during the period. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Trading Up 3.3 %

Shares of Phreesia stock opened at $22.41 on Tuesday. The firm’s 50-day moving average price is $24.15 and its two-hundred day moving average price is $21.36. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of -8.89 and a beta of 0.92. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.02. Phreesia, Inc. has a 12-month low of $12.05 and a 12-month high of $34.98.

Phreesia (NYSE:PHR) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.02. The business had revenue of $95.00 million for the quarter, compared to analyst estimates of $93.52 million. Phreesia had a negative net margin of 38.42% and a negative return on equity of 53.33%. The firm’s revenue for the quarter was up 24.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.72) EPS. On average, analysts forecast that Phreesia, Inc. will post -1.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on PHR shares. DA Davidson reiterated a “neutral” rating and issued a $32.00 price target on shares of Phreesia in a research note on Friday, March 15th. Truist Financial began coverage on Phreesia in a research note on Monday, February 26th. They set a “buy” rating and a $35.00 target price on the stock. Barclays started coverage on Phreesia in a research note on Wednesday, January 3rd. They issued an “overweight” rating and a $29.00 price target for the company. Royal Bank of Canada reiterated a “sector perform” rating and set a $23.00 price objective on shares of Phreesia in a research report on Thursday, March 21st. Finally, Stephens restated an “overweight” rating and issued a $28.00 price target on shares of Phreesia in a research note on Friday, March 22nd. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, Phreesia presently has a consensus rating of “Moderate Buy” and an average target price of $31.62.

Insider Buying and Selling

In other Phreesia news, General Counsel Allison C. Hoffman sold 1,238 shares of Phreesia stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $22.86, for a total value of $28,300.68. Following the transaction, the general counsel now owns 135,621 shares in the company, valued at $3,100,296.06. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Janet Gunzburg sold 1,709 shares of the company’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $22.62, for a total transaction of $38,657.58. Following the completion of the transaction, the insider now directly owns 38,900 shares in the company, valued at $879,918. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Allison C. Hoffman sold 1,238 shares of the firm’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $22.86, for a total value of $28,300.68. Following the sale, the general counsel now directly owns 135,621 shares in the company, valued at approximately $3,100,296.06. The disclosure for this sale can be found here. Insiders sold a total of 82,989 shares of company stock worth $1,911,735 in the last ninety days. 5.80% of the stock is owned by insiders.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.